Early TAVR Surveillance Cost-Effectiveness Analysis Demonstrates Economic Dominance

New research on early TAVR surveillance cost-effectiveness indicates that immediate transcatheter aortic valve replacement (eTAVR) delivers superior clinical outcomes and lower lifetime expenditures than clinical surveillance for patients with asymptomatic severe aortic stenosis. A recent economic evaluation grounded in the EARLY TAVR randomized trial projects that eTAVR generates 0.21 additional life-years and 0.24 additional quality-adjusted life-years per patient while reducing total payer costs by $8,812.

Model Captures Decades of Event-Driven Outcomes

A Markov cohort model structured around 30-day cycles and three core health states—alive and well, post-stroke, and death—projects patient trajectories from a mean age of 75.8 years to 100 or death. Transition probabilities, utilities, and event rates for the first five years come directly from the EARLY TAVR trial, with parametric survival models and age-adjusted mortality multipliers used thereafter. Costs reflect contemporary Medicare reimbursement inflated to 2022–2023 dollars, differentiated by valve type, symptom status, and complications such as permanent pacemaker implantation. Extensive one-way, probabilistic, and scenario analyses tested the stability of the dominance finding.

Savings Driven by Fewer Strokes and Late-Stage Procedures

Early TAVR surveillance cost-effectiveness stems from three key mechanisms: a lower lifetime weighted cost of the valve procedure itself, reduced stroke-related spending, and fewer heart-failure hospitalizations. Although eTAVR fronts the full procedural cost in the first cycle, the surveillance arm accumulates higher expenses once patients become symptomatic, with index hospitalization payments rising 13–15 percent and cumulative costs surpassing eTAVR by approximately year three. The bulk of quality-adjusted life-year gains occur in the highest-utility “alive-and-well” state.

Ad

Dominance Holds Across Wide Range of Assumptions

Early TAVR surveillance cost-effectiveness remained robust in 5,000 probabilistic iterations, with 95.9 percent of simulations falling below a $100,000 per QALY threshold and 90.3 percent demonstrating outright cost-saving dominance. Deterministic sensitivity analysis identified discount rates and stroke utilities as the most influential variables, yet none overturned the base-case result. The economic advantage proved consistent even when real-world delays in treatment, higher symptom burdens at crossover, and alternative reintervention rates were modeled.

Payers Could See Long-Term Budget Relief

From a U.S. healthcare payer perspective, the three-year breakeven point suggests that earlier adoption of eTAVR could materially reduce lifetime budgetary exposure while improving population-level health, especially as the Medicare population with aortic stenosis expands. The trial-derived framework offers HEOR teams and policymakers a transparent foundation for coverage decisions that weigh upfront procedural investment against downstream event avoidance and sustained quality of life.